Abstract
Real World Efficacy of BCMA Directed Therapies in Patients with Multiple Myeloma after Receiving Belantamab Mafodotin
Transplantation and cellular therapy, Vol.31(2), pp.S414-S415
02/2025
DOI: 10.1016/j.jtct.2025.01.635
Abstract
Multiple myeloma is an inherently incurable plasma cell malignancy characterized by periods of remissions and inevitable relapses. Belantamab mafodotin, an anti-BCMA ADC was previously approved for patients that have failed ≥4 prior therapies.While BCMA directed therapies with different mechanisms of action are increasingly utilized for RRMM, outcomes after sequential therapies with BCMA directed treatments remains an area of active investigation. This study aims to assess the real-world outcomes of patients treated with BCMA-directed therapies following progression on belantamab mafodotin.
This retrospective analysis was conducted on adult patients with RRMM who had received belantamab mafodotin and were subsequently treated with BCMA directed therapies from October 10, 2019 to September 28, 2023. This multicenter study was a collaborative effort of five large academic centers in the US Myeloma Innovations Research Collaborative (USMIRC). Key outcomes included response rates, progression free survival (PFS) and overall survival (OS). Subgroup analyses were performed to compare patients who received bispecific antibodies (BsAb) or CAR T-cell therapy, as well as those who had a ≥6-month interval versus those with a <6 month interval between belantamab mafodotin and subsequent BCMA therapy. The PFS and OS were estimated using the Kaplan-Meier curves.
A total of 23 patients (12 males, 11 females) were included in the analysis. The median age was 68 (range 37-82) years with 10 patients (43%) with high-risk cytogenetics, 20 patients (87%) who had received at least ≥4 prior lines of treatment, and 8 patients (35%) with extra medullary disease (EMD) at the time of treatment. Of these 23 patients, 14 received CAR-T and 9 received BsAb. The overall response rate (ORR) for the entire population was 65% (15/23), 44% (4/9) in the BsAb subgroup and 79% (11/14) in the CAR-T subgroup. With a median follow up of 24 months for the entire population, median PFS and OS were 5 (range 2-10) months and 28 (16-NR) months, respectively. There was no statistically significant difference in median PFS between patients who received a BsAb (5 mos, range 2-10) versus CAR-T (7 mos range 2-9) (p= 0.8); Figure 1. When comparing the timing of subsequent BCMA directed therapy, no statistically significant difference was seen between BCMA therapy within 6 months (5 mos, range 3-9) and BCMA therapy ≥ 6-month post belantamab (7 mos, range 2-10) (p= 0.8) Figure 2.
In patients with RRMM receiving BCMA directed BsAb or CAR T-cell therapy after failure of belantamab mafodotin, outcomes in general remain inferior compared to those without prior BCMA exposure (historical cohort). Choice of subsequent BCMA directed therapy as well as treatment free interval from BCMA exposure are not predictive of outcomes. Our findings need to be confirmed with larger studies and longer follow-up.
Details
- Title: Subtitle
- Real World Efficacy of BCMA Directed Therapies in Patients with Multiple Myeloma after Receiving Belantamab Mafodotin
- Creators
- Rachel DiLeo - Allegheny Health NetworkPrerna Mewawalla - US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KSKalaivani Babu - Allegheny Health NetworkYue Yin - Allegheny-Singer Research InstituteChristopher Sun Strouse - US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KSEthan Chen - University of IowaHira Shaikh - US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KSJames Davis - US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KSKimberly Green - US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KSOmar Alkharabsheh - US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KSAliya Rashid - US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KSBidushi Pokhrel - University of Kansas Medical CenterNausheen Ahmed - US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KSAl-Ola Abdallah - US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KSHamza Hashmi - Memorial Sloan Kettering Cancer Center
- Resource Type
- Abstract
- Publication Details
- Transplantation and cellular therapy, Vol.31(2), pp.S414-S415
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.jtct.2025.01.635
- ISSN
- 2666-6367
- eISSN
- 2666-6367
- Language
- English
- Date published
- 02/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984795478902771
Metrics
1 Record Views